Trump’s Drug-Pricing Push to Cut Access Outside US, Study Finds
The Trump administration’s push to bring US drug spending down is a powerful incentive for pharmaceutical companies to boost prices and reduce access elsewhere in the world, a study found.
By Naomi Kresge · Bloomberg Markets
The Trump administration’s push to bring US drug spending down is a powerful incentive for pharmaceutical companies to boost prices and reduce access elsewhere in the world, a study found.